Webinar: Resurrecting Antibody Genus Protection – Allowed Claims Through CDR-Scanning
New antibody patenting strategies, such as structure-based genus and means-plus-function claims, are reshaping how antibody genus claims are being written post Amgen v. Sanofi. Join us on Thursday, March 5, at 12 PM ET, as we discuss examples of antibody genus claims recently allowed by the USPTO based on these strategies. This webinar will explore: New antibody claim strategies that…